Zomig Nasal Related Published Studies
Well-designed clinical trials related to Zomig Nasal (Zolmitriptan)
Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. [2011.05]
Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. [2011.02]
Efficacy of frovatriptan in the acute treatment of menstrually related migraine:
analysis of a double-blind, randomized, multicenter, Italian, comparative study
versus zolmitriptan. [2011]
Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. [2010.06]
Frovatriptan versus zolmitriptan for the acute treatment of migraine: a
double-blind, randomized, multicenter, Italian study. [2010]
Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. [2009.07]
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. [2008.12.20]
Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. [2007.08.28]
Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. [2006.11]
Effectiveness of Intranasal Zolmitriptan in Acute Cluster Headache: A Randomized, Placebo-Controlled, Double-blind Crossover Study. [2006.09.11]
Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. [2006.08.08]
Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. [2006.05]
Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. [2006.01]
Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. [2006]
Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study. [2005.10]
Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial. [2005.03]
Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study. [2005.01]
Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. [2005]
Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. [2004.11]
Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. [2004.02]
Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. [2004]
Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. [2003.12]
Zolmitriptan nasal spray: advances in migraine treatment. [2003.10.28]
Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. [2003.09]
Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. [2003]
Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. [2003]
Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers. [2002.11]
Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study. [2002.06]
Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. [2002.03]
Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. [2002]
Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. [2001.05]
Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder. [2000.09]
Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. [2000.06]
Oral zolmitriptan is effective in the acute treatment of cluster headache. [2000.05.09]
Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. [2000.02]
A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. [2000.02]
Effects of zolmitriptan (Zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine. [1999.03]
Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache. [1999]
Zolmitriptan provides consistent migraine relief when used in the long-term. [1999]
A long-term study to maximise migraine relief with zolmitriptan. [1999]
Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers. [1998.12]
The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. [1998.11]
Effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers. [1998.09]
Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. [1998.08]
Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. [1998.06]
The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. [1998.03]
The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). [1997.12]
Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). [1997.12]
Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. [1997.11]
Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. [1997.11]
Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. [1997.10]
Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. [1997.10]
The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). [1997.06]
The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. [1997.03]
The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. [1997]
Well-designed clinical trials possibly related to Zomig Nasal (Zolmitriptan)
Gender and triptan efficacy: a pooled analysis of three double-blind, randomized,
crossover, multicenter, Italian studies comparing frovatriptan vs. other
triptans. [2014]
Efficacy of frovatriptan and other triptans in the treatment of acute migraine of
hypertensive and normotensive subjects: a review of randomized studies. [2013]
Frovatriptan vs. other triptans for the acute treatment of oral
contraceptive-induced menstrual migraine: pooled analysis of three double-blind,
randomized, crossover, multicenter studies. [2013]
Triptans in prevention of menstrual migraine: a systematic review with
meta-analysis. [2013]
Antimigraine efficacy of telcagepant based on patient's historical triptan response. [2011.01]
Acute and preventive pharmacologic treatment of cluster headache. [2010.08.03]
Nitroglycerin provocation in normal subjects is not a useful human migraine model? [2010.08]
Acute and preventive pharmacologic treatment of cluster headache. [2010]
Triptans for acute cluster headache. [2010]
A review of recent clinical experience with almotriptan. [2006]
Multiple attack study on the available triptans in Italy versus placebo. [2005.07]
Impact of antimigraine compounds on cognitive processing: a placebo-controlled crossover study. [2003.11]
Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. [2002.06.11]
Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. [2002]
Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. [2002]
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. [2001.05]
Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. [2001.04]
Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. [2000.11.22]
Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. [2000.10]
The scientific basis of medication choice in symptomatic migraine treatment. [1999.11]
The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. [1999.08]
The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. [1996.02]
311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. [1996.02]
Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura? [1996]
Other research related to Zomig Nasal (Zolmitriptan)
Zolmitriptan and human aggression: interaction with alcohol. [2010.07]
Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. [2010.05]
Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. [2010.04]
Prinzmetal-variant angina in a patient using zolmitriptan and citalopram. [2010.02]
Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery. [2009.10.08]
Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies. [2009.10]
Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo. [2009.06]
Male-specific induction of CYP3A2 in rats by zolmitriptan. [2008.12]
Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. [2008.02]
Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. [2008]
Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. [2007.12]
Patient preference for triptan formulations: a prospective study with zolmitriptan. [2007.09]
Efficacy of zolmitriptan nasal spray in adolescent migraine. [2007.08]
Almotriptan and zolmitriptan in the acute treatment of migraine. [2007.01]
Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study. [2007]
Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet. [2006.12]
[Symptomatic treatment of migraine with zolmitriptan: experience with 82 patients] [2006.05]
[Experience with intranasal zolmitriptan in cluster headache] [2006.04]
Determination of zolmitriptan in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. [2006.02.17]
Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. [2006.01]
Renal infarction during the use of rizatriptan and zolmitriptan: two case reports. [2006]
Distribution of intranasal C-zolmitriptan assessed by positron emission tomography. [2005.12]
|